The estimated Net Worth of Panna Sharma is at least $1.32 Million dollars as of 16 March 2016. Mr Sharma owns over 1,500 units of Lantern Pharma stock worth over $567,300 and over the last 11 years he sold LTRN stock worth over $0. In addition, he makes $750,492 as Pres und CEO & Director at Lantern Pharma.
Mr has made over 4 trades of the Lantern Pharma stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 1,500 units of LTRN stock worth $3,885 on 16 March 2016.
The largest trade he's ever made was buying 1,500 units of Lantern Pharma stock on 16 March 2016 worth over $3,885. On average, Mr trades about 455 units every 0 days since 2013. As of 16 March 2016 he still owns at least 152,500 units of Lantern Pharma stock.
You can see the complete history of Mr Sharma stock trades at the bottom of the page.
Panna Sharma is the Pres, CEO & Director at Lantern Pharma.
As the Pres und CEO & Director of Lantern Pharma, the total compensation of Mr Sharma at Lantern Pharma is $750,492. There are no executives at Lantern Pharma getting paid more.
Mr Sharma is 50, he's been the Pres und CEO & Director of Lantern Pharma since . There are 2 older and no younger executives at Lantern Pharma. The oldest executive at Lantern Pharma Inc. is Dr. Kishor Gopaldas Bhatia Ph.D., 66, who is the Chief Scientific Officer & Scientific Consultant.
Panna's mailing address filed with the SEC is 1920 MCKINNEY AVENUE, 7TH FLOOR, , DALLAS, TX, 75201.
Over the last 4 years, insiders at Lantern Pharma have traded over $6,373,290 worth of Lantern Pharma stock and bought 10,000 units worth $150,000 . The most active insiders traders include Aaron G.L.Bios Fund I, Lpbi..., Leslie W.Cavu Management, L... und Maria Luisa Maccecchini. On average, Lantern Pharma executives and independent directors trade stock every 111 days with the average trade being worth of $423,325. The most recent stock trade was executed by Leslie W.Cavu Management, L... on 23 May 2024, trading 30,000 units of LTRN stock currently worth $189,000.
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas.
Lantern Pharma executives and other stock owners filed with the SEC include: